• Je něco špatně v tomto záznamu ?

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy

R. Mikyšková, I. Štěpánek, M. Indrová, J. Bieblová, J. Šímová, I. Truxová, I. Moserová, J. Fučíková, J. Bartůňková, R. Špíšek, M. Reiniš,

. 2016 ; 48 (3) : 953-64. [pub] 20151229

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000713

High hydrostatic pressure (HHP) has been shown to induce immunogenic cell death of cancer cells, facilitating their uptake by dendritic cells (DC) and subsequent presentation of tumor antigens. In the present study, we demonstrated immunogenicity of the HHP-treated tumor cells in mice. HHP was able to induce immunogenic cell death of both TC-1 and TRAMP-C2 tumor cells, representing murine models for human papilloma virus-associated tumors and prostate cancer, respectively. HHP-treated cells induced stronger immune responses in mice immunized with these tumor cells, documented by higher spleen cell cytotoxicity and increased IFNγ production as compared to irradiated tumor cells, accompanied by suppression of tumor growth in vivo in the case of TC-1 tumors, but not TRAMP-C2 tumors. Furthermore, HHP-treated cells were used for DC-based vaccine antigen pulsing. DC co-cultured with HHP-treated tumor cells and matured by a TLR 9 agonist exhibited higher cell surface expression of maturation markers and production of IL-12 and other cytokines, as compared to the DC pulsed with irradiated tumor cells. Immunization with DC cell-based vaccines pulsed with HHP-treated tumor cells induced high immune responses, detected by increased spleen cell cytotoxicity and elevated IFNγ production. The DC-based vaccine pulsed with HHP-treated tumor cells combined with docetaxel chemotherapy significantly inhibited growth of both TC-1 and TRAMP-C2 tumors. Our results indicate that DC-based vaccines pulsed with HHP-inactivated tumor cells can be a suitable tool for chemoimmunotherapy, particularly with regard to the findings that poorly immunogenic TRAMP-C2 tumors were susceptible to this treatment modality.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000713
003      
CZ-PrNML
005      
20170118113246.0
007      
ta
008      
170103s2016 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ijo.2015.3314 $2 doi
024    7_
$a 10.3892/ijo.2015.3314 $2 doi
035    __
$a (PubMed)26718011
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Mikyšková, Romana $u Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
245    10
$a Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy / $c R. Mikyšková, I. Štěpánek, M. Indrová, J. Bieblová, J. Šímová, I. Truxová, I. Moserová, J. Fučíková, J. Bartůňková, R. Špíšek, M. Reiniš,
520    9_
$a High hydrostatic pressure (HHP) has been shown to induce immunogenic cell death of cancer cells, facilitating their uptake by dendritic cells (DC) and subsequent presentation of tumor antigens. In the present study, we demonstrated immunogenicity of the HHP-treated tumor cells in mice. HHP was able to induce immunogenic cell death of both TC-1 and TRAMP-C2 tumor cells, representing murine models for human papilloma virus-associated tumors and prostate cancer, respectively. HHP-treated cells induced stronger immune responses in mice immunized with these tumor cells, documented by higher spleen cell cytotoxicity and increased IFNγ production as compared to irradiated tumor cells, accompanied by suppression of tumor growth in vivo in the case of TC-1 tumors, but not TRAMP-C2 tumors. Furthermore, HHP-treated cells were used for DC-based vaccine antigen pulsing. DC co-cultured with HHP-treated tumor cells and matured by a TLR 9 agonist exhibited higher cell surface expression of maturation markers and production of IL-12 and other cytokines, as compared to the DC pulsed with irradiated tumor cells. Immunization with DC cell-based vaccines pulsed with HHP-treated tumor cells induced high immune responses, detected by increased spleen cell cytotoxicity and elevated IFNγ production. The DC-based vaccine pulsed with HHP-treated tumor cells combined with docetaxel chemotherapy significantly inhibited growth of both TC-1 and TRAMP-C2 tumors. Our results indicate that DC-based vaccines pulsed with HHP-inactivated tumor cells can be a suitable tool for chemoimmunotherapy, particularly with regard to the findings that poorly immunogenic TRAMP-C2 tumors were susceptible to this treatment modality.
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny nádorové $x metabolismus $7 D000951
650    _2
$a antitumorózní látky $x aplikace a dávkování $7 D000970
650    _2
$a protinádorové vakcíny $x chemie $7 D019496
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cytotoxicita imunologická $7 D003602
650    _2
$a dendritické buňky $x cytologie $7 D003713
650    _2
$a lidé $7 D006801
650    _2
$a hydrostatický tlak $7 D006874
650    _2
$a imunitní systém $7 D007107
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a interferon gama $x metabolismus $7 D007371
650    _2
$a interleukin-12 $x metabolismus $7 D018664
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a experimentální nádory $x farmakoterapie $x terapie $7 D009374
650    _2
$a infekce papilomavirem $x farmakoterapie $x terapie $7 D030361
650    _2
$a nádory prostaty $x farmakoterapie $x metabolismus $x terapie $7 D011471
650    _2
$a slezina $x imunologie $7 D013154
650    _2
$a taxoidy $x aplikace a dávkování $7 D043823
650    _2
$a toll-like receptor 9 $x metabolismus $7 D051217
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Štěpánek, Ivan $u Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Indrová, Marie $u Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Bieblová, Jana $u Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Šímová, Jana $u Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Truxová, Iva $u SOTIO a.s., Prague, Czech Republic.
700    1_
$a Moserová, Irena $u SOTIO a.s., Prague, Czech Republic.
700    1_
$a Fučíková, Jitka $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Bartůňková, Jiřina $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Špíšek, Radek $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Reiniš, Milan $u Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
773    0_
$w MED00002350 $t International journal of oncology $x 1791-2423 $g Roč. 48, č. 3 (2016), s. 953-64
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26718011 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170118113353 $b ABA008
999    __
$a ok $b bmc $g 1179853 $s 961280
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 48 $c 3 $d 953-64 $e 20151229 $i 1791-2423 $m International journal of oncology $n Int J Oncol $x MED00002350
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...